In brief: Ipsen closes Clementia acquisition

In brief: Ipsen closes Clementia acquisition
Credit: Shutterstock.com/ ASDF_MEDIA

Ipsen has closed its acquisition of Canada’s Clementia Pharmaceuticals after securing approval from shareholders and the Quebec Superior Court.

Clementia shareholders will receive $25.00 per share in cash up front and one contingent value right (CPV) per share entitling them to receive $6.00 per CVR upon the US FDA acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas.

Clarissa Desjardins, Clementia CEO, said: “Going forward, we are confident that Ipsen, with its shared patient-centric culture, proven development capabilities and global commercial footprint, will fulfil our ambition of delivering palovarotene to patients worldwide as quickly as possible.”